Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wall Street Zen to "Buy" Rating

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Saturday.

A number of other analysts have also recently weighed in on ALNY. Citigroup boosted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Royal Bank Of Canada boosted their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. Stifel Nicolaus upped their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. BMO Capital Markets upped their target price on shares of Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a research note on Tuesday, June 24th. Finally, William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-two have assigned a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $341.91.

Alnylam Pharmaceuticals Trading Down 2.0%

Shares of ALNY stock traded down $6.63 during trading hours on Friday, reaching $317.50. 972,968 shares of the stock traded hands, compared to its average volume of 856,566. Alnylam Pharmaceuticals has a 1-year low of $205.87 and a 1-year high of $333.70. The business has a fifty day moving average price of $297.55 and a 200 day moving average price of $267.35. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. The firm has a market capitalization of $41.40 billion, a PE ratio of -151.91 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The company had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. During the same period in the previous year, the firm posted ($0.16) earnings per share. The business's revenue for the quarter was up 20.2% on a year-over-year basis. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the sale, the chief executive officer owned 48,948 shares in the company, valued at $14,978,088. This trade represents a 28.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ALNY. SVB Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $27,000. Whipplewood Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 71 shares in the last quarter. Bessemer Group Inc. lifted its stake in Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares in the last quarter. Larson Financial Group LLC lifted its stake in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 73 shares in the last quarter. Finally, Park Square Financial Group LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $28,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.